Cardiol Therapeutics (CRDL) Equity Ratio: 2021-2022
Historic Equity Ratio for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to 2.15.
- Cardiol Therapeutics' Equity Ratio fell 24.08% to 2.15 in Q3 2022 from the same period last year, while for Sep 2022 it was 2.15, marking a year-over-year decrease of 24.08%. This contributed to the annual value of 0.87 for FY2021, which is N/A change from last year.
- Cardiol Therapeutics' Equity Ratio amounted to 2.15 in Q3 2022, which was up 11.52% from 1.93 recorded in Q2 2022.
- In the past 5 years, Cardiol Therapeutics' Equity Ratio ranged from a high of 1,800,933.84 in Q1 2022 and a low of 0.87 during Q4 2021.
- Moreover, its 2-year median value for Equity Ratio was 2.04 (2022), whereas its average is 300,157.25.
- Examining YoY changes over the last 5 years, Cardiol Therapeutics' Equity Ratio showed a top increase of 1.80% in 2022 and a maximum decrease of 24.08% in 2022.
- Over the past 2 years, Cardiol Therapeutics' Equity Ratio (Quarterly) stood at 0.87 in 2021, then fell by 24.08% to 2.15 in 2022.
- Its Equity Ratio was 2.15 in Q3 2022, compared to 1.93 in Q2 2022 and 1,800,933.84 in Q1 2022.